SCHEMBL30785587

SCHEMBL30785587

Cc1cc(C(F)(F)F)c(CNC(=O)OC(C)(C)C)c(=O)[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNA1H O95180 1/20 0.49
▸ CACNA1B Q00975 1/20 0.49
▸ CACNA1C Q13936 1/20 0.49
▸ EZH2 Q15910 12/20 0.47
▸ EED O75530 8/20 0.47
▸ RBBP4 Q09028 8/20 0.47
▸ SUZ12 Q15022 8/20 0.47
▸ AEBP2 Q6ZN18 8/20 0.47
▸ KDM4E B2RXH2 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ GLA P06280 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ EZH1 Q92800 1/20 0.43
▸ LMNA P02545 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ KDM4A O75164 1/20 0.38
▸ PRMT5 O14744 1/20 0.37
▸ WDR77 Q9BQA1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16120372 0.84 EZH2 (0.51) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL16377050 0.82 EZH2 (0.43) CACNA1HCACNA1BCACNA1CEZH2EED
SCHEMBL25930340 0.81 EZH2 (0.48) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL17885417 0.81 EZH2 (0.46) CACNA1HCACNA1BCACNA1CEZH2EED
SCHEMBL19964708 0.81 EZH2 (0.49) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL21500329 0.80 EZH2 (0.46) EZH2
SCHEMBL2595917 0.79 EZH2 (0.40) CACNA1HCACNA1BCACNA1CEZH2EED
SCHEMBL25930841 0.78 EZH2 (0.41) CACNA1HCACNA1BCACNA1CEZH2EED
SCHEMBL9887625 0.76 EZH2 (0.45) EZH2EEDRBBP4SUZ12AEBP2
SCHEMBL18455533 0.76 HPGD (0.53) EZH2EEDRBBP4SUZ12AEBP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008788-A1 AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) 2026-01-08 — — US disclosed
EP-4596554-A1 AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE Suzhou Arkbiopharmaceutical Co., Ltd. (CN) 2025-08-06 — — EP disclosed
CN-119698422-A Aza condensed ring compound, preparation method and medical application thereof 苏州爱科百发生物医药技术有限公司 2025-03-25 — — CN disclosed
WO-2024067660-A1 AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE 苏州爱科百发生物医药技术有限公司 2024-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008788-A1 AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE PDE4B, PDE4A, CYP4A11 CACNA1H 978/4885CACNA1B 615/4885CACNA1C 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback